Thalidomide induces haematologic responses in patients with -thalassaemia
Thalidomide induces haematologic responses in patients with -thalassaemia
复制标题
DOI：
10.1111/ejh.12955
复制
发表时间：
2017-11-01
影响因子：
3.1
通讯作者：
Huang, Lan
中科院分区：
文献类型：
--
作者：
Chen, Jiangming;Zhu, Weijian;Huang, Lan
目的本研究旨在评价沙利度胺治疗的重型或中型地中海贫血患者的临床和实验室结果。方法通过分析地中海贫血患者的病历获得临床和实验室数据。采用自身对照法，检测治疗前后血红蛋白（Hb）、胎儿血红蛋白（HbF）、白细胞（WBC）和血小板水平，并记录不良反应。结果对9例患者的病历数据进行分析。这些患者的中位血红蛋白水平从治疗前的5.132.15g/dL增加至治疗后的10.38+/-1.19g/dL。平均脾脏大小从治疗前的 8.19 +/- 3.10 长度减少到治疗后肋缘以下的 5.49 +/- 1.80 厘米。在可进行这些测量的 9 名患者中，平均 HbF 水平从治疗前的 35.67%+/- 26.82% 增加到治疗后的 75.67%+/- 14.64%。所有患者在治疗后1个月不再需要输血。所有接受沙利度胺治疗的患者均未观察到严重不良反应。结论在本研究中，沙利度胺对需要频繁红细胞输注的地中海贫血患者显示出显着的疗效。沙利度胺可增加血红蛋白水平，不会引起严重不良反应，但应持续观察长期疗效和其他副作用。
ObjectiveThis study aimed to evaluate the clinical and laboratory outcomes of a group of patients with -thalassaemia major or intermedia treated with thalidomide.MethodsClinical and laboratory data were obtained by analysing medical records of -thalassaemia patients. Using the self-control method, the levels of haemoglobin (Hb), foetal haemoglobin (HbF), white blood cells (WBC) and platelets were detected before and after the treatment, and adverse reactions were recorded.ResultsData from the medical records of 9 patients were analysed. The median haemoglobin levels of these patients increased from 5.132.15g/dL before treatment to 10.38 +/- 1.19g/dL after treatment. The average spleen size decreased from a pretreatment length of 8.19 +/- 3.10 to 5.49 +/- 1.80cm below the costal margin after treatment. The mean HbF levels increased from a pretreatment value of 35.67%+/- 26.82% to 75.67%+/- 14.64% after treatment in the 9 patients for whom these measurements were available. All patients no longer needed transfusions by 1month after treatment. No serious adverse reactions were observed in any of the thalidomide-treated patients.ConclusionIn this study, thalidomide showed an outstanding effect on -thalassaemia patients who required frequent red-cell transfusions. Thalidomide increased haemoglobin levels without causing serious adverse reactions, but the long-term curative outcomes and other side effects should be observed continuously.